Atezolizumab + Nab-Paclitaxel Well Tolerated and Active in Metastatic TNBC

June 3-7, 2016; Chicago, Illinois
Phase Ib trial of combination therapy with atezolizumab and nab-paclitaxel showed a safety profile similar to each agent alone and produced durable responses in patients with mTNBC.
Format: Microsoft PowerPoint (.ppt)
File Size: 571 KB
Released: June 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Laura M. Spring, MD, discusses the use of abemaciclib in patients with HR-positive, HER2-negative, node-positive early breast cancer, from Clinical Care Options (CCO)

Laura M. Spring, MD Released: November 29, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the use of targeted therapies for advanced biliary tract cancer

Mark Yarchoan, MD Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue